PTC Therapeutics reports Q2 2026 revenue of $361 million, raises full-year guidanceJul 30Quarterly updatePTC Therapeuticssepiapterin
PTC Therapeutics registers Phase 3 PROVE-FA trial for vatiquinone in Friedreich's AtaxiaJul 2Trial updatePTC Therapeuticsvatiquinone
Sign inSign in